WO1995001442A3 - Nucleotide and amino acid sequences of the envelope 1 gene of 51 hepatitis c virus isolates and the use of reagents derived therefrom as diagnostic reagents and vaccines - Google Patents

Nucleotide and amino acid sequences of the envelope 1 gene of 51 hepatitis c virus isolates and the use of reagents derived therefrom as diagnostic reagents and vaccines Download PDF

Info

Publication number
WO1995001442A3
WO1995001442A3 PCT/US1994/007320 US9407320W WO9501442A3 WO 1995001442 A3 WO1995001442 A3 WO 1995001442A3 US 9407320 W US9407320 W US 9407320W WO 9501442 A3 WO9501442 A3 WO 9501442A3
Authority
WO
WIPO (PCT)
Prior art keywords
reagents
envelope
vaccines
hepatitis
nucleotide
Prior art date
Application number
PCT/US1994/007320
Other languages
French (fr)
Other versions
WO1995001442A2 (en
Inventor
Jens Bukh
Roger H Miller
Robert H Purcell
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Priority to AU73191/94A priority Critical patent/AU7319194A/en
Publication of WO1995001442A2 publication Critical patent/WO1995001442A2/en
Publication of WO1995001442A3 publication Critical patent/WO1995001442A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle

Abstract

The nucleotide and deduced amino acid sequences of 51 cDNAs are disclosed where each cDNA encodes the envelope 1 gene of an isolate of hepatitis C virus (HCV). The invention relates to the oligonucleotides, peptides and recombinant envelope 1 proteins derived from these sequences and their use in diagnostic methods and vaccines.
PCT/US1994/007320 1993-06-29 1994-06-28 Nucleotide and amino acid sequences of the envelope 1 gene of 51 hepatitis c virus isolates and the use of reagents derived therefrom as diagnostic reagents and vaccines WO1995001442A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU73191/94A AU7319194A (en) 1993-06-29 1994-06-28 Nucleotide and amino acid sequences of the envelope 1 gene of 51 hepatitis c virus isolates and the use of reagents derived therefrom as diagnostic reagents and vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/086,428 1993-06-29
US08/086,428 US5514539A (en) 1993-06-29 1993-06-29 Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines

Publications (2)

Publication Number Publication Date
WO1995001442A2 WO1995001442A2 (en) 1995-01-12
WO1995001442A3 true WO1995001442A3 (en) 1995-08-10

Family

ID=22198509

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/007320 WO1995001442A2 (en) 1993-06-29 1994-06-28 Nucleotide and amino acid sequences of the envelope 1 gene of 51 hepatitis c virus isolates and the use of reagents derived therefrom as diagnostic reagents and vaccines

Country Status (3)

Country Link
US (3) US5514539A (en)
AU (1) AU7319194A (en)
WO (1) WO1995001442A2 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
US7255997B1 (en) * 1993-04-27 2007-08-14 N.V. Innogenetics S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
BR9405334A (en) 1993-04-27 1999-05-25 Innogenetics Nv New hepatitis c virus genotype sequences and their use as therapeutic and diagnostic agents
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US5882852A (en) * 1993-06-29 1999-03-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hepatitic C virus (HCV) core gene nucleotide sequences and related methods of detecting major and minor genotypes of HCV isolates
US7070790B1 (en) 1993-06-29 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US5874563A (en) * 1994-05-20 1999-02-23 Genelabs Technologies, Inc. Hepatitis G virus and molecular cloning thereof
US20040185061A1 (en) * 1994-07-29 2004-09-23 Innogenetics N.V. Redox reversible HCV proteins with native-like conformation
ES2174957T5 (en) 1994-07-29 2006-12-16 Innogenetics N.V. PURIFIED PROTEINS OF HEPATITIS C VIRUS WRAPPING FOR DIAGNOSTIC AND THERAPEUTIC USE.
AU702436B2 (en) 1994-10-21 1999-02-18 Innogenetics N.V. New sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
US5851759A (en) * 1996-04-19 1998-12-22 Chiron Corporation Heteroduplex tracking assay (HTA) for genotyping HCV
WO1997047358A1 (en) * 1996-06-11 1997-12-18 Merck & Co., Inc. Synthetic hepatitis c genes
US20050074752A1 (en) * 1996-06-11 2005-04-07 Merck & Co., Inc. Synthetic hepatitis C genes
US5849800A (en) * 1997-03-28 1998-12-15 The Penn State Research Foundation Use of amantadine for treatment of Hepatitis C
ES2563643T3 (en) * 1997-04-01 2016-03-15 Illumina Cambridge Limited Nucleic acid sequencing method
EP0947525A1 (en) * 1998-03-27 1999-10-06 Innogenetics N.V. Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue
US7108855B2 (en) * 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
AR021833A1 (en) 1998-09-30 2002-08-07 Applied Research Systems METHODS OF AMPLIFICATION AND SEQUENCING OF NUCLEIC ACID
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
JP2002528140A (en) 1998-11-05 2002-09-03 ザ ボード オブ トラスティーズ オブ リーランド スタンフォード ジュニア ユニバーシティ Human PAN-HCV human monoclonal antibody
US7074556B2 (en) * 1999-03-02 2006-07-11 Invitrogen Corporation cDNA synthesis improvements
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
AR031640A1 (en) * 2000-12-08 2003-09-24 Applied Research Systems ISOTHERMAL AMPLIFICATION OF NUCLEIC ACIDS IN A SOLID SUPPORT
AU2002311897A1 (en) * 2001-05-09 2002-11-18 Third Wave Technologies, Inc. Nucleic acid detection in pooled samples
US7196183B2 (en) 2001-08-31 2007-03-27 Innogenetics N.V. Hepatitis C virus genotype, and its use as prophylactic, therapeutic and diagnostic agent
DE02800437T1 (en) * 2001-10-03 2004-11-11 The President And Fellows Of Harvard College, Cambridge COPOLYMERS FOR SUPPRESSING AUTOIMMUNE DISEASES AND METHODS OF USE
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US20040210035A1 (en) * 2002-01-30 2004-10-21 Straten Eivind Per Thor Survivin-derived peptides and use thereof
CA2502649A1 (en) * 2002-10-18 2004-04-29 Nucleonics Inc. Double-stranded rna structures and constructs, and methods for generating and using the same
JP5250179B2 (en) * 2002-11-08 2013-07-31 ザ アドミニストレイターズ オブ ザ テューレイン エデュケイショナル ファンド Flavivirus fusion inhibitor
US8124747B2 (en) * 2003-08-29 2012-02-28 Innogenetics HCV clade and prototype sequences thereof
JP2007514413A (en) * 2003-11-12 2007-06-07 プロジェニクス・ファーマスーティカルズ・インコーポレイテッド Novel sequence encoding hepatitis C virus glycoprotein
GB0522310D0 (en) 2005-11-01 2005-12-07 Solexa Ltd Methods of preparing libraries of template polynucleotides
GB0524069D0 (en) * 2005-11-25 2006-01-04 Solexa Ltd Preparation of templates for solid phase amplification
EP2021503A1 (en) * 2006-03-17 2009-02-11 Solexa Ltd. Isothermal methods for creating clonal single molecule arrays
EP2121991A2 (en) 2006-10-20 2009-11-25 Innogenetics N.V. Methodology for analysis of sequence variations within the hcv ns3/4a genomic region
EP2463389A1 (en) 2006-10-20 2012-06-13 Innogenetics N.V. Methodology for analysis of sequence variations within the HCV NS5B genomic region
US8043803B2 (en) * 2006-12-06 2011-10-25 Cornell Research Foundation, Inc. Slitrks as markers for stem and progenitor cells and methods of use thereof
WO2008093098A2 (en) 2007-02-02 2008-08-07 Illumina Cambridge Limited Methods for indexing samples and sequencing multiple nucleotide templates
WO2009034190A2 (en) * 2007-09-14 2009-03-19 Genimmune N.V. Affinity tag
US20100029748A1 (en) * 2008-08-04 2010-02-04 Sloan-Kettering Institute For Cancer Research Metastasis Promoting Genes and Proteins
WO2010038042A1 (en) 2008-10-02 2010-04-08 Illumina Cambridge Ltd. Nucleic acid sample enrichment for sequencing applications
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
US8182994B2 (en) 2009-09-15 2012-05-22 Illumina Cambridge Limited Centroid markers for image analysis of high denisty clusters in complex polynucleotide sequencing

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0468527A2 (en) * 1990-07-26 1992-01-29 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and prevention thereof as vaccines
EP0485209A1 (en) * 1990-11-08 1992-05-13 Immuno Japan Inc. Non A, non B hepatitis virus related antigen, antibody detection systems, polynucleotides and polypeptides
WO1992008734A1 (en) * 1990-11-08 1992-05-29 Chiron Corporation Hepatitis c virus asialoglycoproteins
WO1992011370A2 (en) * 1990-12-21 1992-07-09 Boehringer Mannheim Gmbh Polypeptides derived from proteins of the hepatitis c virus
EP0510952A1 (en) * 1991-04-26 1992-10-28 Immuno Japan Inc. Oligonucleotide primers and their application for high-fidelity detection of non-a, non-b hepatitis virus
WO1992019743A2 (en) * 1991-05-08 1992-11-12 Chiron Corporation Hcv genomic sequences for diagnostics and therapeutics
WO1992021759A1 (en) * 1991-06-06 1992-12-10 Institut Pasteur Nucleotide and peptide sequences of an isolate of the hepatitis c virus, diagnostic and therapeutic applications thereof
WO1993002103A1 (en) * 1991-07-19 1993-02-04 Sorin Biomedica S.P.A. Epitopes of the env protein of the hepatitis c virus
EP0532167A2 (en) * 1991-08-09 1993-03-17 Immuno Japan Inc. Non-A, Non-B Hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
WO1993006126A1 (en) * 1991-09-13 1993-04-01 Chiron Corporation Immunoreactive hepatitis c virus polypeptide compositions
WO1993015193A1 (en) * 1992-01-31 1993-08-05 Abbott Laboratories Mammalian expression systems for hcv proteins
EP0585549A2 (en) * 1992-06-11 1994-03-09 JAPAN as represented by Director General of Agency of NATIONAL INSTITUTE OF HEALTH Method for producing ectoprotein of hepatitis C virus
WO1994025601A2 (en) * 1993-04-27 1994-11-10 N.V. Innogenetics S.A. New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358535A (en) * 1980-12-08 1982-11-09 Board Of Regents Of The University Of Washington Specific DNA probes in diagnostic microbiology
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
YU48038B (en) * 1987-11-18 1996-10-18 Chiron Corp. PROCEDURE FOR DIAGNOSIS OF NO-A, NO-V HEPATITIS
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
HU227547B1 (en) * 1991-06-24 2011-08-29 Novartis Vaccines & Diagnostic Hepatitis c virus (hcv) polypeptides
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0468527A2 (en) * 1990-07-26 1992-01-29 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and prevention thereof as vaccines
EP0485209A1 (en) * 1990-11-08 1992-05-13 Immuno Japan Inc. Non A, non B hepatitis virus related antigen, antibody detection systems, polynucleotides and polypeptides
WO1992008734A1 (en) * 1990-11-08 1992-05-29 Chiron Corporation Hepatitis c virus asialoglycoproteins
WO1992011370A2 (en) * 1990-12-21 1992-07-09 Boehringer Mannheim Gmbh Polypeptides derived from proteins of the hepatitis c virus
EP0510952A1 (en) * 1991-04-26 1992-10-28 Immuno Japan Inc. Oligonucleotide primers and their application for high-fidelity detection of non-a, non-b hepatitis virus
WO1992019743A2 (en) * 1991-05-08 1992-11-12 Chiron Corporation Hcv genomic sequences for diagnostics and therapeutics
WO1992021759A1 (en) * 1991-06-06 1992-12-10 Institut Pasteur Nucleotide and peptide sequences of an isolate of the hepatitis c virus, diagnostic and therapeutic applications thereof
WO1993002103A1 (en) * 1991-07-19 1993-02-04 Sorin Biomedica S.P.A. Epitopes of the env protein of the hepatitis c virus
EP0532167A2 (en) * 1991-08-09 1993-03-17 Immuno Japan Inc. Non-A, Non-B Hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
WO1993006126A1 (en) * 1991-09-13 1993-04-01 Chiron Corporation Immunoreactive hepatitis c virus polypeptide compositions
WO1993015193A1 (en) * 1992-01-31 1993-08-05 Abbott Laboratories Mammalian expression systems for hcv proteins
EP0585549A2 (en) * 1992-06-11 1994-03-09 JAPAN as represented by Director General of Agency of NATIONAL INSTITUTE OF HEALTH Method for producing ectoprotein of hepatitis C virus
WO1994025601A2 (en) * 1993-04-27 1994-11-10 N.V. Innogenetics S.A. New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
Abstracts of 3rd Intl Conf. Current trends in chronically evolving viral hepatitis 4-7 Oct 1992, Pisa, Italy *
C. ISHIDA ET AL.: "Detection of antibodies to heaptitis C virus structural proteins", J. CLIN. MICRO., vol. 31, no. 4, 1993, pages 936 - 940 *
H. HADA ET AL.: "Sequence variation in the envelope protein of hepatitis C virus", ACTA MED OKAYAMA, vol. 45, no. 5, 1991, pages 347 - 355 *
H. HSU ET AL.: "Charactreisation of HCV structural proteins with a recombinant baculovirus expression system", HEPATOLOGY, vol. 17, no. 5, 1993, pages 763 - 771 *
H. OKAMOTO ET AL.: "Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier", J. GEN. VIROL., vol. 72, 1991, pages 2697 - 2704 *
H. OKAMOTO ET AL: "Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates", VIROLOGY, vol. 188, 1992, pages 331 - 341 *
J. BUKH ET AL.: "At least 12 genotypes of heaptitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide", PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 8234 - 8238 *
J. Hepatol., vol. 17, suppl. 1, 1992, p. S10, Abstract no. l12 Vaccine approaches to HCV M. Houghton et al. *
L. STUYVER ET AL.: "Analysis of the putative E1 envelope and NS4a epitope regions of HCV Type 3", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 192, no. 2, 1993, pages 635 - 641 *
L. STUYVER ET AL.: "Classification of hepatitis C viruses based on phylogenetic analysis of envelope 1 and nonstructural 5B regions and identification of 5 additional subtypes", PROC. NATL ACAD. SCI. USA, vol. 91, 1994, pages 10134 - 10138 *
M. KOHARA ET AL.: "Expression and characterisation of glycoprotein gp35 of hepatit is C virus using recombinant vaccinia virus", J. GEN. VIROL., vol. 73, 1992, pages 2313 - 2318 *
M. SALLBERG ET AL: "Antigenic regions within the heaptitis C virus envelope and nonstructural proteins", CLIN. EXP. IMMUNOL., vol. 91, no. 3, 1993, pages 489 - 494 *
T. CHA ET AL.: "Ar least five related but distinct hepatitis C viral genotypes exist", PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 7144 - 7148 *
Y. MATSUURA ET AL.: "Expression of processed envelope protein of hepatitis C virus in mammalian and insect cells", J. VIROL., vol. 66, 1992, pages 1425 - 1431 *

Also Published As

Publication number Publication date
US6572864B1 (en) 2003-06-03
AU7319194A (en) 1995-01-24
WO1995001442A2 (en) 1995-01-12
US5514539A (en) 1996-05-07
US5871962A (en) 1999-02-16

Similar Documents

Publication Publication Date Title
WO1995001442A3 (en) Nucleotide and amino acid sequences of the envelope 1 gene of 51 hepatitis c virus isolates and the use of reagents derived therefrom as diagnostic reagents and vaccines
WO1996005315A3 (en) Nucleotide and amino acid sequences of the envelope 1 and core genes of hepatitis c virus
EP0939128A3 (en) New HCV isolates
CA2263889A1 (en) P-selectin ligand proteins
HK1050215A1 (en) Dna fragments of the gag gene of lav.
CA2253636A1 (en) Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof
CA2196555A1 (en) Vr-2332 viral nucleotide sequence and methods of use
WO1998004702A3 (en) Proteins, in particular membrane proteins, of helicobacter pylori, their preparation and use
WO1992019743A3 (en) Hcv genomic sequences for diagnostics and therapeutics
CA2158455A1 (en) Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide and their uses in vaccines and disease treatments
CA2283464A1 (en) Functional dna clone for hepatitis c virus (hcv) and uses thereof
AU2197392A (en) Hepatitis C virus from C-100-3 and env/core regions
WO2004085633A8 (en) A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof
CA2170515A1 (en) Nucleotide sequences for novel protein tyrosine phosphatases
CA2045323A1 (en) Non-a, non-b hepatitis virus genomic cdna and antigen polypeptide
WO2004048402B1 (en) A hepatitis c virus codon optimized non-structural ns3/4a fusion gene
CA2115579A1 (en) Ryegrass pollen allergen
WO2000012535A3 (en) Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
WO2004087062A3 (en) Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
WO1996040764A3 (en) Nucleotide and amino acid sequences of hypervariable region 1 of the envelope 2 gene of hepatitis c virus
BG105065A (en) A vaccine-induced hepatitis b viral strain and uses thereof
WO1996021020A3 (en) Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
AU5776799A (en) Modified hcv peptide vaccines
GR3027636T3 (en) Anti-feline immunodeficiency virus (fiv) vaccines.
WO2002074960A3 (en) 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA